Skip to main content
SpringerLink
Log in

Safety, efficacy and total costs of multiple myeloma regimens

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Dhakal B, et al. Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma regimens: A Bayesian network meta-analysis of phase 3 randomized controlled trials. Cancer : 10 Mar 2020. Available from: URL: http://doi.org/10.1002/cncr.32831

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Safety, efficacy and total costs of multiple myeloma regimens. Reactions Weekly 1796, 12 (2020). https://doi.org/10.1007/s40278-020-76299-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-020-76299-7

Search

Navigation